- Home
- BDTX vs CYBN Comparison
BDTX vs CYBN Comparison
Compare BDTX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- CYBN
- Stock Information
- Founded
- BDTX 2014
- CYBN 2019
- Country
- BDTX United States
- CYBN Canada
- Employees
- BDTX N/A
- CYBN N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- CYBN Pharmaceuticals and Biotechnology
- Sector
- BDTX Health Care
- CYBN Health Care
- Exchange
- BDTX Nasdaq
- CYBN Nasdaq
- Market Cap
- BDTX 181.4M
- CYBN 147.4M
- IPO Year
- BDTX 2020
- CYBN N/A
- Fundamental
- Price
- BDTX $3.80
- CYBN $7.38
- Analyst Decision
- BDTX Strong Buy
- CYBN Strong Buy
- Analyst Count
- BDTX 5
- CYBN 3
- Target Price
- BDTX $10.40
- CYBN $85.00
- AVG Volume (30 Days)
- BDTX 904.0K
- CYBN 1.0M
- Earning Date
- BDTX 11-05-2025
- CYBN 11-12-2025
- Dividend Yield
- BDTX N/A
- CYBN N/A
- EPS Growth
- BDTX N/A
- CYBN N/A
- EPS
- BDTX 0.25
- CYBN N/A
- Revenue
- BDTX $70,000,000.00
- CYBN N/A
- Revenue This Year
- BDTX N/A
- CYBN N/A
- Revenue Next Year
- BDTX N/A
- CYBN N/A
- P/E Ratio
- BDTX $15.26
- CYBN N/A
- Revenue Growth
- BDTX N/A
- CYBN N/A
- 52 Week Low
- BDTX $1.20
- CYBN $4.81
- 52 Week High
- BDTX $4.45
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- BDTX 49.08
- CYBN 68.26
- Support Level
- BDTX $3.67
- CYBN $6.86
- Resistance Level
- BDTX $4.08
- CYBN $8.00
- Average True Range (ATR)
- BDTX 0.24
- CYBN 0.38
- MACD
- BDTX -0.06
- CYBN 0.18
- Stochastic Oscillator
- BDTX 10.26
- CYBN 77.07
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.